Ambavane, Apoorva <br/><br/>
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.  [electronic resource] 

 -  Immunotherapy  01 2020 
 - 37-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1750-7448 
<br/><br/><label>Standard No.: </label>10.2217/imt-2019-0199  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Antineoplastic Protocols<br/>Carcinoma, Renal Cell--drug therapy<br/>Computer Simulation<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Humans<br/>Ipilimumab--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Models, Economic<br/>Neoplasm Staging<br/>Nivolumab--therapeutic use<br/>Quality-Adjusted Life Years<br/>Survival Analysis<br/>Treatment Outcome